Respiratory Syncytial Virus Transplacental Antibody Transfer and Kinetics in Mother-Infant Pairs in Bangladesh

Journal of Infectious Diseases

Volumn 210, Issue 10, 2014, Pages 1582-1589

  Chu, Helen Y ^a   Steinhoff, Mark C ^c   Magaret, Amalia ^a   Zaman, Khalequ ^e   Roy, Eliza ^e   Langdon, Gretchen ^c   Formica, Mary Anne ^d   Walsh, Edward E ^d   Englund, Janet A ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

antibody.; maternal vaccine; respiratory syncytial virus

Indexed keywords

MATERNAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; AUTUMN; BANGLADESH; BIRTH; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HALF LIFE TIME; HUMAN; INFANT; MALE; MATERNAL SERUM; PUERPERIUM; SENSITIVITY ANALYSIS; SEROLOGY; SPRING; SUMMER; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; VIRUS NEUTRALIZATION; WINTER; ADOLESCENT; BLOOD; FETOMATERNAL TRANSFUSION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; NEWBORN; PASSIVE IMMUNIZATION; PERINATAL PERIOD; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ANTIBODIES, VIRAL; BANGLADESH; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT; INFANT, NEWBORN; MALE; MATERNAL-FETAL EXCHANGE; PERIPARTUM PERIOD; PREGNANCY; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; YOUNG ADULT;

EID: 84912062240     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu316     Document Type: Article

References (38)

1. Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. Lancet 2013; 381:1405-16.
2. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-Analysis. Lancet 2011; 378:1917-30.
3. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588-98.
4. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98:708-15.
5. Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J 2008; 27:207-12.
6. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 1981; 7:263-71.
7. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7.
8. Piedra PA, Jewell AM, Cron SG, Atmar RL, GlezenWP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003; 21:3479-82.
9. Shinoff JJ, OBrien KL, Thumar B, et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008; 198:1007-15.
10. Englund J, Glezen WP, Piedra PA. Maternal immunization against viral disease. Vaccine 1998; 16:1456-63.
11. Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis 1993; 168:647-56.
12. Adedinsewo DA, Noory L, Bednarczyk RA, et al. Impact of maternal characteristics on the effect of maternal influenza vaccination on fetal outcomes. Vaccine 2013; 31:5827-33.
13. Lindsey B, Kampmann B, Jones C. Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis 2013; 26:248-53.
14. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis 2013; 56:539-44.
15. Okoko BJ,Wesumperuma HL, Fern J, Yamuah LK, Hart CA. The transplacental transfer of IgG subclasses: influence of prematurity and low birthweight in the Gambian population. Ann Trop Paediatr 2002; 22:325-32.
16. Mulholland K, Suara RO, Siber G, et al. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. JAMA 1996; 275:1182-8.
17. Farquhar C, Nduati R, Haigwood N, et al. High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. J Acquir Immune Defic Syndr 2005; 40:494-7.
18. Cox MJ, Azevedo RS, Cane PA, Massad E, Medley GF. Seroepidemiological study of respiratory syncytial virus in Sao Paulo state, Brazil. J Med Virol 1998; 55:234-9.
19. Suara RO, Piedra PA, Glezen WP, et al. Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States. Clin Diagn Lab Immunol 1996; 3:477-9.
20. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003; 21:3465-7.
21. Ochola R, Sande C, Fegan G, et al. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PloS One 2009; 4:e8088.
22. Brandenburg AH, Groen J, van Steensel-Moll HA, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997; 52:97-104.
23. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013; 31(suppl 2):B209-15.
24. Rudan I, Nair H, Marusic A, Campbell H. Reducing mortality from childhood pneumonia and diarrhoea: The leading priority is also the greatest opportunity. J Glob Health 2013; 3:10101.
25. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359: 1555-64.
26. Oken E, Kleinman KP, Rich-Edwards J, Gillman MW. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr 2003; 3:6.
27. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997; 15:1130-2.
28. Murphy BR, Graham BS, Prince GA, et al. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol 1986; 23:1009-14.
29. Henkle E, Steinhoff MC, Omer SB, et al. Incidence of influenza virus infection in early infancy: a prospective study in South Asia. Pediatr Infect Dis J 2011; 30:170-3.
30. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 1996; 14:1214-8.
31. Falsey AR, Walsh EE, Looney RJ, et al. Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J Med Virol 1999; 59:221-6.
32. Sande CJ, Mutunga MN, Okiro EA, Medley GF, Cane PA, Nokes DJ. Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort. J Med Virol 2013; 85:2020-5.
33. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratorysyncytial- virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979; 300: 530-4.
34. Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae. Am J Epidemiol 1975; 101:532-51.
35. Kim HW, Arrobio JO, Brandt CD, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol 1973; 98:216-25.
36. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985; 55:517-20.
37. Stockman LJ, Brooks WA, Streatfield PK, et al. Challenges to evaluating respiratory syncytial virus mortality in Bangladesh, 2004-2008. PLoS One 2013; 8:e53857.
38. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2009; 123: 398-403